Can Epsilon-aminocaproic Acid improving postrecirculation hemodynamics and reduce intraliver activated protein C consumption in orthotopic liver transplantation

Epsilon-aminocaproic Acid used during orthotopic liver transplantation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001662

Enrollment

Unknown

Registered

2011-11-03

Start date

2009-11-03

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coagulation function disturbance during OLT

Interventions

two groups:Epsilon-aminocaproic Acid, APC

Eligibility

Sex/Gender

All

Age

20 Years to 67 Years

Inclusion criteria

Inclusion criteria: In all consecutive patients undergoing OLT in our liver transplantation center.

Exclusion criteria

Exclusion criteria: The exclusion criteria were: 1) Budd-Chiari syndrome; 2) acute liver failure; 3) early retransplantation (less than one month); 4) simultaneous kidney and liver transplantation or renal insufficiency with dialysis; and 5) primary familial amyloidotic neuropathy.

Design outcomes

Primary

Measure	Time frame
APC;	—

Countries

China

Contacts

Public ContactKong HY

hzkhy@163.com+86 13615816337

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026